Management of peritoneal carcinomatosis from colorectal cancer: review of the literature.

Autor: Vallicelli C; Unit of Surgery and Advanced Oncologic Therapies, Morgagni-Pierantoni Hospital, Forlì, Italy, carlovallicelli@hotmail.it., Cavaliere D, Catena F, Coccolini F, Ansaloni L, Poiasina E, Abongwa HK, De Simone B, Alberici L, Framarini M, Verdecchia GM
Jazyk: angličtina
Zdroj: International journal of colorectal disease [Int J Colorectal Dis] 2014 Aug; Vol. 29 (8), pp. 895-8. Date of Electronic Publication: 2014 Jun 11.
DOI: 10.1007/s00384-014-1907-x
Abstrakt: Background: Today, we do not have a universally accepted evidence on how to treat peritoneal carcinomatosis (PC) from colorectal cancer (CRC) in international guidelines.
Methods: The present study is a review of the literature investigating current strategies to treat CRC PC.
Results: Despite the progresses of systemic chemotherapy, the presence of PC among patients with metastatic CRC reduces the overall survival to 30 %, and only 4 % of patients with PC from CRC treated are alive for 5 years. Many trials evaluate the combined treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for CRC PC, suggesting a survival benefit in highly selected patients. Only one trial is randomized and presents some biases. The two main prognostic factors are Peritoneal Cancer Index (PCI) and completeness of cytoreduction score (CC score). There is no universal agreement on how to approach the synchronous presence of PC and liver metastasis with a curative intent during the same procedure. A growing interest among the scientific community has arisen about systematic second-look surgery and HIPEC treatment in high-risk patients.
Conclusion: Current evidences suggest that CRS and HIPEC might be beneficial in highly selected patients affected with PC from CRC. Anyway, today, there is a shortage of well-designed phase 3 trials.
Databáze: MEDLINE
Externí odkaz: